Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
Annals of Surgical Oncology
|
June 28, 2019
Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
Marcia Hall, Konstantinos Savvatis, Katherine Nixon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2018
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Sarah P Blagden, Anne L Hamilton, Linda Mileshkin, et al.
JAMA Network Open
|
February 16, 2023
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer
Chiara A Cella, Maren Knoedler, Marcia Hall, et al.
JAMA Oncology
|
February 6, 2025
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial
Rebecca Kristeleit, Michael-John Devlin, Andrew Clamp, et al.
Therapeutic Advances in Medical Oncology
|
April 15, 2021
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037)
Susana Banerjee, Holly Tovey, Rebecca Bowen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2020
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i>-mutant Ovarian Cancer
Amit M Oza, Maria Estevez-Diz, Eva-Maria Grischke, et al.
Radiology
|
October 2, 2019
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker
Jessica M Winfield, Jennifer C Wakefield, David Dolling, et al.
Gynecologic Oncology
|
May 28, 2019
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903
Linda Mileshkin, Richard Edmondson, Rachel L O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 25, 2013
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study
Ignace B Vergote, Antonio Jimeno, Florence Joly, et al.
The Lancet. Oncology
|
July 3, 2020
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial
Sarah P Blagden, Adrian D Cook, Christopher Poole, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
Annals of Surgical Oncology
|
June 28, 2019
Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
Marcia Hall, Konstantinos Savvatis, Katherine Nixon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2018
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Sarah P Blagden, Anne L Hamilton, Linda Mileshkin, et al.
JAMA Network Open
|
February 16, 2023
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer
Chiara A Cella, Maren Knoedler, Marcia Hall, et al.
JAMA Oncology
|
February 6, 2025
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial
Rebecca Kristeleit, Michael-John Devlin, Andrew Clamp, et al.
Therapeutic Advances in Medical Oncology
|
April 15, 2021
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037)
Susana Banerjee, Holly Tovey, Rebecca Bowen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2020
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i>-mutant Ovarian Cancer
Amit M Oza, Maria Estevez-Diz, Eva-Maria Grischke, et al.
Radiology
|
October 2, 2019
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker
Jessica M Winfield, Jennifer C Wakefield, David Dolling, et al.
Gynecologic Oncology
|
May 28, 2019
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903
Linda Mileshkin, Richard Edmondson, Rachel L O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 25, 2013
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study
Ignace B Vergote, Antonio Jimeno, Florence Joly, et al.
The Lancet. Oncology
|
July 3, 2020
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial
Sarah P Blagden, Adrian D Cook, Christopher Poole, et al.
Page
of 8